Walter V. Klemp is CEO & President at Moleculin Biotech, Inc. (MBRX). They have made 7 open-market trades across 1 company since 2017, most recently 2026-09-03.
CIK 0000938419
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $1.0M since 2017, against 1 sale. Across 6 scored buys the stock is up 43.5% at ninety days, and 39.5 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 83% | 50% | 50% |
| Avg Move | +11.8% | +18.2% | +43.5% |
| Alpha | +11.1% | +18.9% | +39.5% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MBRX | BUY | 2025-06-23 | 2025-06-23 | $0.37 | $500K | +19.3% | +148.7% | +43.3% |
| MBRX | BUY | 2023-12-26 | 2023-12-27 | $0.69 | $260K | -4.0% | -35.2% | -58.4% |
| MBRX | BUY | 2022-11-25 | 2022-11-28 | $1.28 | $58K | +6.7% | -14.9% | -8.6% |
| MBRX | BUY | 2022-11-21 | 2022-11-23 | $1.15 | $26K | +1.6% | -4.7% | +0.0% |
| MBRX | BUY | 2022-11-16 | 2022-11-18 | $0.98 | $191K | +27.0% | +12.6% | +15.3% |
| MBRX | SELL | 2017-08-16 | 2017-08-18 | $1.70 | $170K | +7.1% | +4.1% | -32.4% |
| MBRX | BUY | 2017-05-11 | 2017-05-12 | $0.81 | $10K | +20.4% | +2.6% | +269.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.